Research Article
Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
Table 2
Outcome of COVID-19 in IBD patients, disease course of IBD, and vaccination after COVID-19 infection.
| | COVID-19 outcomes | Number of patients (%)a |
| | Asymptomatic | 18 (22.0) | | Mild COVID-19 symptoms | 58 (70.7) | | Hospitalization due to COVID-19/severe COVID-19 | 6 (7.3) | | Duration of hospitalization (day), median (IQR) | 10.5 (3.75–29.0) | | Recovery day after admission, median (IQR) | 12.5 (7.0–25.5) | | COVID-19 pneumonia | 5 (6.1) | | Required mechanical ventilators | 2 (2.4) | | Required intensive care admission | 2 (2.4) | | Dead | 2 (2.4) | | C-reactive protein after COVID-19 (mg/l), median (IQR) | 4 (2.0–12.8) | | Fecal calprotectin after COVID-19 (mcg/g), median (IQR) | 197 (57.5–653.5) | | Flare of IBD disease after COVID-19 infection | 8 (9.8) | | Duration after COVID-19 (weeks), median (IQR) | 9.5 (7.2–12.0) | | C-reactive protein during flare (mg/L), median (IQR) | 8.0 (3.0–42.0) | | Fecal calprotectin during flare (mcg/g), median (IQR) | 1,088.5 (562–2,025) | | Treatment care outcomes | | Loss to follow-up | 15 (18.3) | | Disruption of biologics | 30 (36.6) | | Duration of holding biologics (week), median (IQR) | 3.0 (2.0–5.0) | | Number of patients delayed in endoscopy | 7 (8.5) | | COVID-19 vaccination | 50 (61.0) | | 1-dose vaccine | 39 (47.6) | | 2-dose vaccine | 11 (13.4) |
|
|
aData are presented as number (%) unless indicated otherwise. CD: Crohn’s disease, UC: ulcerative colitis, NA: not available, IQR: interquartile range.
|
